[64] As an unconjugated steroid, finasteride is a highly lipophilic compound
Abstract Purpose: The efficacy of finasteride was assessed in the treatment of gross hematuria associated with benign prostatic hyperplasia (BPH)
Finasteride blocks the action of an enzyme called 5-alpha-reductase
Mechanism of Action Finasteride competitively inhibits type II 5-alpha reductase, resulting in inhibition of the conversion of testosterone to dihydrotestosterone
In this report we address an unusual adverse effect of finasteride (Propecia 1 mg tablets) that was associated with painless hematuria and hematospermia in a 38
Finasteride, a 5␣-reductase inhibitor introduced as drug therapy for BPH, is also used to provide prophylaxis for BPH associated hematuria and decrease blood loss at surgical prostate resection Purpose: We evaluated the influence of finasteride on prostatic microvessel density to elucidate a mechanism of decreased bleeding in finasteride treated patients with hematuria secondary to benign prostatic hyperplasia (BPH)
SURGICAL TREATMENTS We prospectively studied the effect of finasteride on chronic hematuria associated with benign prostatic hyperplasia
0 cases per 100,000 person Generic Name
Finasteride is a synthetic 4-azasteroid compound 13 and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT)
Vascular endothelial growth factor (VEGF), a potent stimulator of angiogenesis, and microvessel density have been independently evaluated in the mechanism of decreased bleeding observed in patients treated with
The exact mechanism of action of finasteride with regard to its effects on hematuria has not yet been clarified
Materials and Methods: A retrospective review was done of 18 patients who had been placed on finasteride (5 mg
1016/S0022-5347(05)64025-6 Corpus ID: 36348881; The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients
Such lack of effects is attributed to the weak Purpose: We evaluate the use of finasteride to control gross hematuria secondary to prostatic bleeding
To determine the mechanism by which finasteride reduces prostate size, tissue was collected at the time of prostatectomy from men taking either no medication (n = 10) or 5 mg finasteride daily for Purpose: We identify predictors of clinical response as well as response time in patients treated with finasteride for gross hematuria due to benign prostatic hyperplasia
found that hematuria Moreover, persistent glomerular hematuria in kidney donors has been associated with an increased risk of proteinuria and kidney disease progression at 2